Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News
Surfen Sie die heißeste Edelmetall-Welle des Jahrzehnts! Dieses TOP-Unternehmen zündet nächste Wachstumsstufe!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
839 Leser
Artikel bewerten:
(2)

Visiongain Report Provides Critical Market-led Data on the $11.7bn Asia Vaccines Market

Asia Vaccines Market Forecast to 2029

Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Influenza, Hepatitis, Polio, Meningococcal, DTP, Rotavirus, MMR, HPV

LONDON, Nov. 26, 2019 /PRNewswire/ -- Asia vaccines market is estimated at $7bn in 2018 and is expected to grow at a CAGR of 8.8% during the first half of the forecast period. The Japanese vaccines market held 30% share of the Asian vaccines market in 2018.

Visiongain Logo

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 178-page report you will receive 82 charts- all unavailable elsewhere.

The 178-page Visiongain report provides clear detailed insight into the Asian vaccines market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/asia-vaccines-market-forecast-to-2029/download_sampe_div

Report Scope

• Asia Vaccines Market revenue forecasts to 2029

• Asia Vaccines Market revenue forecasts to 2029 by Vaccine Technology:
• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines

• Asia Vaccines Market revenue forecasts to 2029 by Indication:
• Influenza
• Hepatitis
• Polio
• Meningococcal
• DTP
• Rotavirus
• MMR
• HPV
• Others

• Asia Vaccines Market revenue forecasts to 2029 by Country:
Japan
China
India
Australia
South Korea
Vietnam
Philippines
Thailand
Indonesia
• Rest of Asia

Further segmented by indication and vaccine technology.

• Profiles of the selected leading companies:
• Astellas
• AstraZeneca
• CSL, Ltd.
• Emergent BioSolutions, Inc.
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Mitsubishi Tanabe Pharma Corporation
• Pfizer
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Sun Pharmaceuticals Industries, Ltd.
• Takeda

• This report provides a Pipeline Analysis

• This report discusses factors that drive and restrain the market. This report also discusses trends and opportunities in the market.

• Key Questions Answered by this Report:
• What is the current size of Asia vaccines market? How much will this market be worth from 2018 to 2029?
• What are the main drivers and restraints that will shape Asia vaccines market over the next ten years?
• What are the main segments within Asia vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the Asian vaccines market? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2029?
• Who are the leading companies and what are their activities, results, developments and prospects?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/asia-vaccines-market-forecast-to-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

Afferent Pharmaceuticals
Affinivax, Inc.
Astellas Pharma
AstraZeneca
Bavarian Nordic
BIKEN Co. Ltd
Biological E. Limited
Biomedical Advanced Research and Development Authority (BARDA)
BioNTech
Cancer Research UK
Chiba University
CSL, Ltd.
Daiichi Sankyo Company, Ltd.
Emergent Biosolutions, Inc.
European Commission
Ganymed Pharmaceuticals AG
GlaxoSmithKline
GlycoVaxyn AG
HitGen
Immunomic Therapeutics, Inc.
Inovio Pharmaceuticals
IOmet
Janssen
Johnson & Johnson
MedImmune
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Moderna
Nanotherapeutics
Osaka University
Oswaldo Cruz Foundation
PaxVax
Pfizer
Potenza Therapeutics, Inc.
Protein Sciences
Sanofi
Seqirus
Serum Institute of India Pvt. Ltd.
Sun Pharmaceuticals Industries, Ltd.
Takeda
University of Oxford
University of Tokyo
Zydus Cadila

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2019-2029

Biologics Market Trends and Forecasts 2019-2029

Global Medical Device Contract Manufacturing Market Forecast 2019-2029

Global Vaccines Sales Market Forecast 2019-2029

Indian Pharmaceutical Market Forecast 2019-2029

mRNA Vaccines and Therapeutics Market Forecast 2019-2029

Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

© 2019 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.